Abstract

During the last years, an extraordinary effort has been made to identify biomarkers as potential tools for improving prevention, diagnosis, drug response and drug development in psychiatric disorders. Contrary to other diseases, mental illnesses are classified by diagnostic categories with a broad variety list of symptoms. Consequently, patients diagnosed from the same psychiatric illness present a great heterogeneity in their clinical presentation. This fact together with the incomplete knowledge of the neurochemical alterations underlying mental disorders, contribute to the limited efficacy of current pharmacological options. In this respect, the identification of biomarkers in psychiatry is becoming essential to facilitate diagnosis through the developing of markers that allow to stratify groups within the syndrome, which in turn may lead to more focused treatment options. In order to shed light on this issue, this review summarizes the concept and types of biomarkers including an operational definition for therapeutic development. Besides, the advances in this field were summarized and sorted into five categories, which include genetics, transcriptomics, proteomics, metabolomics, and epigenetics. While promising results were achieved, there is a lack of biomarker investigations especially related to treatment response to psychiatric conditions. This review includes a final conclusion remarking the future challenges required to reach the goal of developing valid, reliable and broadly-usable biomarkers for psychiatric disorders and their treatment. The identification of factors predicting treatment response will reduce trial-and-error switches of medications facilitating the discovery of new effective treatments, being a crucial step towards the establishment of greater personalized medicine.

Highlights

  • According to World Health Organization mental illness presented devastating rates of prevalence, mortality, morbidity and disability

  • An additional study carried out in patients diagnosed with bipolar disorder (BD) (STEP-BD, Systematic Treatment Enhancement Program for Bipolar Disorder) revealed that only 24% of patients experienced a remission of depression during 8 consecutive weeks, outcome similar to those observed in the vehicle group [6]

  • This review provides an overview about the current state of biomarkers in neuropsychiatry, with the ultimate aim of remarking some goals achieved up to date and the future challenges needed to develop valid, reliable and broadly-usable biomarkers for psychiatric disorders and their treatment

Read more

Summary

Introduction

According to World Health Organization mental illness presented devastating rates of prevalence, mortality, morbidity and disability. Prognostic Biomarker Commonly used to identify the probability of developing a clinical event in patients diagnosed with a disease or medical condition [16].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.